BioCentury
ARTICLE | Clinical News

ALT-801: Phase Ib/II data

July 20, 2015 7:00 AM UTC

Data from 34 chemotherapy-refractory patients in the dose-escalation and expansion stages of an open-label, U.S. Phase Ib/II trial showed that 0.06 mg/kg IV ALT-801 plus gemcitabine with or without cisplatin led to an ORR of 35%, including 3 complete responses and 9 partial responses, plus 7 cases of stable disease. In chemotherapy-refractory patients, median PFS was 3.2 months and median OS was 11.7 months. The most common treatment-related grade 3/4 adverse events reported were thrombocytopenia, neutropenia, anemia, lymphopenia, rash and hypophosphatemia. ...